EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial

Luca Malorni, Giampaolo Bianchini, Roberta Caputo, Alberto Zambelli, Fabio Puglisi, Giulia V Bianchi, Lucia Del Mastro, Ida Paris, Filippo Montemurro, Giacomo Allegrini, Marco Colleoni, Stefano Tamberi und 9 weitere

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.03.001 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Luca Malorni und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Translational Research Unit "Sandro Pitigliani", Ospedale di Prato, Azienda USL Toscana Centro, Italy. Electronic address:…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Farmacéutica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleLetrozoleProportional Hazards ModelsThymidine KinaseProspective StudiesAntineoplastic Combined Chemotherapy ProtocolsAminopyridinesAromatase InhibitorsBiomarkersErb-b2 Receptor Tyrosine KinasesPurines

Stichwörter der Autor:innen

Advanced breast cancerBiomarkerLetrozoleRibociclibThymidine kinase

Substanzen

LetrozoleThymidine KinaseAminopyridinesAromatase InhibitorsBiomarkersErb-b2 Receptor Tyrosine KinasesribociclibPurines

Autor:innen und Institutionen

  • Department of Oncology and Translational Research Unit "Sandro Pitigliani", Ospedale di Prato, Azienda USL Toscana Centro, Italy. Electronic address: Luca.malorni@uslcentro.toscana.it.
  • Department of Oncology, Ospedale San Raffaele, Milano, Italy.
  • Department of Breast and Thoracic Oncology, IRCCS Istituto Nazionale dei Tumori Fondazione G Pascale, Napoli, Italy.
  • Medical Oncology Unit, IRCCS Humanitas Research Hospital and Department of Biomedical Sciences - Humanitas University, Milano, Italy.
  • Department of Medical Oncology, IRCCS, Centro di Riferimento Oncologico,Aviano, Italy; Department of Medicine, University of Udine, Italy.
  • SC Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Förderung

  • Novartis Farmacéutica

Zitieren

APA

Malorni, L., Bianchini, G., Caputo, R., Zambelli, A., Puglisi, F., Bianchi, G. V., Del Mastro, L., Paris, I., Montemurro, F., Allegrini, G., Colleoni, M., Tamberi, S., Zamagni, C., Cazzaniga, M. E., Orditura, M., Guarneri, V., Castelletti, D., Benelli, M., Di Marino, M., …, & De Laurentiis, M. (2023). Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.03.001

Vancouver

Malorni L, Bianchini G, Caputo R, Zambelli A, Puglisi F, Bianchi GV, et al. Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.03.001

BibTeX
@article{Malorni2023,
  author = {Malorni, Luca and Bianchini, Giampaolo and Caputo, Roberta and Zambelli, Alberto and Puglisi, Fabio and Bianchi, Giulia V and Del Mastro, Lucia and Paris, Ida and Montemurro, Filippo and Allegrini, Giacomo and Colleoni, Marco and Tamberi, Stefano and Zamagni, Claudio and Cazzaniga, Marina E and Orditura, Michele and Guarneri, Valentina and Castelletti, Daniela and Benelli, Matteo and Di Marino, Mariacristina and Arpino, Grazia and De Laurentiis, Michelino},
  title = {Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.03.001}
}
Kostenlos starten →